Results 21 to 30 of about 273,161 (350)

Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: evidence from 14-year followup in the West of Scotland Cancer Network [PDF]

, 2011
Clinically and biologically, nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) has much more in common with germinal-center derived B-cell non-Hodgkin lymphoma (NHL) than with classical Hodgkin lymphoma (cHL).
Diehl V, Fanale MA, Hasenclever D, Katrina Farrell, Mike Leach, Orlandi E, Pamela Mckay, Savage KJ, Stein H   +8 more
core   +1 more source

Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the non-Hodgkin Lymphoma Berlin-Frankfurt-Münster protocols

Haematologica, 2017
Mature B-cell non-Hodgkin lymphoma is the most common subtype of non-Hodgkin lymphoma in childhood and adolescence. B-cell non-Hodgkin lymphomas are further classified into histological subtypes, with Burkitt lymphoma and Diffuse large B-cell lymphoma ...
Marius Rohde, Bettina R. Bonn, Martin Zimmermann, Jonas Lange, Anja Möricke, Wolfram Klapper, Ilske Oschlies, Monika Szczepanowski, Inga Nagel, Martin Schrappe, MMML-MYC-SYS Project, ICGC MMML-Seq Project, Markus Loeffler, Reiner Siebert, Alfred Reiter, Birgit Burkhardt   +15 more
doaj   +1 more source

Primary extranodal non-Hodgkin lymphomas of the uterus and the breast: report of three cases [PDF]

, 1995
The authors describe one case of a rare primitive non-Hodgkin lymphoma of the uterus, and two cases of primary non-Hodgkin lymphoma of the breast. Histologically, the uterine lymphoma, although clinically confined to the uterus, was a diffuse large cell ...
Amato, C., CIPOLLA, Calogero, GEBBIA, Nicolo', GEBBIA, Vittorio, Lampasona, G., Latteri, M.   +5 more
core   +1 more source

Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children.

New England Journal of Medicine, 2020
BACKGROUND Rituximab added to chemotherapy prolongs survival among adults with B-cell cancer. Data on its efficacy and safety in children with high-grade, mature B-cell non-Hodgkin's lymphoma are limited.
V. Minard-Colin, A. Aupérin, M. Pillon, G. Burke, D. Barkauskas, K. Wheatley, Rafael F Delgado, S. Alexander, A. Uyttebroeck, C. Bollard, J. Zsiros, M. Csóka, B. Kazanowska, A. Chiang, R. Miles, A. Wotherspoon, P. Adamson, G. Vassal, C. Patte, T. Gross   +19 more
semanticscholar   +1 more source

Non-Hodgkin's lymphoma: A review

Journal of Family Medicine and Primary Care, 2020
Lymphomas constitute the third most common neoplasm in head and neck region arising from the lymphoreticular system. Malignant lymphomas are divided into Hodgkin's disease and non-Hodgkin's lymphoma (NHL).
Rohit Singh, S. Shaik, B. Negi, J. Rajguru, Pankaj Patil, Dr. Anuj S. Parihar, Uma Sharma   +6 more
semanticscholar   +1 more source

CD47 Blockade by Hu5F9‐G4 and Rituximab in Non‐Hodgkin's Lymphoma

New England Journal of Medicine, 2018
Background The Hu5F9‐G4 (hereafter, 5F9) antibody is a macrophage immune checkpoint inhibitor blocking CD47 that induces tumor‐cell phagocytosis. 5F9 synergizes with rituximab to eliminate B‐cell non‐Hodgkin's lymphoma cells by enhancing macrophage ...
R. Advani, I. Flinn, L. Popplewell, A. Forero, N. Bartlett, N. Ghosh, J. Kline, M. Roschewski, A. LaCasce, G. Collins, T. Tran, J. Lynn, J. Chen, J. Volkmer, B. Agoram, Jie Huang, R. Majeti, I. Weissman, C. Takimoto, M. Chao, Sonali M. Smith   +20 more
semanticscholar   +1 more source

DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.

Journal of Clinical Oncology, 2019
PURPOSE Indolent non-Hodgkin lymphoma (iNHL) remains largely incurable and often requires multiple lines of treatment after becoming refractory to standard therapies.
I. Flinn, Carole B. Miller, K. Ardeshna, S. Tetreault, S. Assouline, J. Mayer, M. Merli, S. Lunin, A. Pettitt, Z. Nagy, O. Tournilhac, K. Abou-Nassar, M. Crump, E. Jacobsen, S. de Vos, V. Kelly, Weiliang Shi, L. Steelman, N. Le, D. Weaver, S. Lustgarten, N. Wagner-Johnston, P. Zinzani   +22 more
semanticscholar   +1 more source

NON-HODGKIN'S LYMPHOMA

Pediatric Clinics of North America, 1997
Pediatric lymphomas are the third most common group of malignancies in children and adolescents. Unlike lymphomas in adults, pediatric lymphomas are diffuse, aggressive neoplasms with a propensity for widespread dissemination. Intensification of conventional treatment approaches along with improvements in supportive care have resulted in dramatic ...
A, Shad, I, Magrath
openaire   +2 more sources

Gastric cancer is the leading cause of death in Italian adult patients with common variable immunodeficiency [PDF]

, 2018
An increased prevalence of malignant lymphoma and of gastric cancer has been observed in large cohorts of patients with common variable immunodeficiency (CVID), the most frequently symptomatic primary immunodeficiency. Surveillance strategies for cancers
Agostini, Carlo, Cinetto, Francesco, Crescenzi, Ludovica, Milito, Cinzia, Pecoraro, Antonio, Pulvirenti, Federica, Quinti, Isabella, Rizzo, Francesca, Santangeli, Enrico, Spadaro, Giuseppe, Tabolli, Stefano, Valente, Michele   +11 more
core   +3 more sources

Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma

bioRxiv, 2019
B-cell non-Hodgkin’s lymphoma (B-NHL) encompasses multiple clinically and phenotypically distinct subtypes of malignancy with unique molecular etiologies.
Michael R. Green, Non-Hodgkin Lymphoma, Man Chun, John Man-shun Ma, Saber Tadros, Alyssa Bouska, Tayla B. Heavican, Haopeng Yang, Q. Deng, D. Moore, A. Akhter, K. Hartert, N. Jain, Jordan Showell, Sreejoyee Ghosh, L. Street, M. Davidson, Christopher D. Carey, J. Tobin, Deepak Perumal, J. Vose, M. Lunning, A. Sohani, Benjamin J Chen, S. Buckley, L. Nastoupil, R. Davis, J. Westin, N. Fowler, S. Parekh, M. Gandhi, S. Neelapu, D. Stewart, K. Bhalla, J. Iqbal, T. Greiner, S. Rodig, A. Mansoor   +37 more
semanticscholar   +1 more source